New cancer pill enters first human tests for advanced solid tumors
NCT ID NCT06328439
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental oral drug called ANS014004 in 40 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then expanding to see if the drug can shrink tumors. The main focus is on safety and side effects, with tumor response measured every 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ANS014004 (an oral drug)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so the main goal is safety, not effectiveness. The drug may not work or could cause side effects, and it will take years of further testing before it might become available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China